Free tool
Drug Trial Radar: Gastroenterology and liver
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
4
Not yet recruiting, industry sponsors, Gastroenterology and liver, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed310
4 trials
Showing 1 to 4, recently updated first.
- Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)Pivotal-lookingNot yet recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07933328 · 120 participants (planned) · Start Dec 9, 2026 · Primary completion May 7, 2029
Drug: ALN-CIDEB; Placebo · For: Alcohol-Associated Liver Disease; ALD
- Huanghou Zhixie Diwan in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)Pivotal-lookingNot yet recruiting
Lei Yunshang GroupIndustry
NCT07721012 · 120 participants (planned) · Start Jul 31, 2026 · Primary completion Aug 31, 2027
Drug: Huanghou Zhixie Diwan group; Huanghou Zhixie Diwan mimic · For: Patients With Irritable Bowel Syndrome With Diarrhea
Sites: Beijing, China; Changsha, China; Daqing, China · 14 sites in all
- A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic SteatohepatitisNot yet recruiting
Sinew Pharma Inc.Industry
NCT03468556 · 80 participants (planned) · Start Apr 1, 2026 · Primary completion Apr 30, 2027
Drug: SNP-610; Placebo Oral Tablet · For: NASH - Nonalcoholic Steatohepatitis
- TH104 for the Treatment of Pruritus in Primary Biliary CholangitisNot yet recruiting
Tharimmune IncIndustry
NCT06733519 · 40 participants (planned) · Start Jun 1, 2026 · Primary completion Mar 1, 2027
Drug: Nalmefene; Placebo · For: Pruritus; Primary Biliary Cholangitis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.